News Headlines

  1. Clinical Leader Strengthens Editorial Advisory Board
    1/14/2019

    Clinical Leader, the pharmaceutical industry’s leading online resource for clinical trial analysis and opinion, is dedicated to streamlining the clinical research process by connecting trial sponsors with cutting edge service providers to speed medicines to patients. Our goal is to facilitate connections and improve collaborations by providing valuable information on CROs, sponsors, and advancements in clinical trials.

  2. Significant Number Of Drugs Will Launch For The Treatment Of Age-Related Macular Degeneration By 2026, Says GlobalData
    1/10/2019

    The age-related macular degeneration (AMD) market has been dominated by big pharma companies and their pipeline candidates are ensuring a share of this lucrative market, in spite of patent expiries of their highly-priced products, according to GlobalData, a leading data and analytics company.

  3. Nobilis Therapeutics Enters Into Collaboration With The Linde Group To Support Its Clinical Research Program For PTSD And Other CNS Disorders
    1/10/2019

    Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative Central Nervous System therapies based on the use of noble gas mixtures, recently announced that it has entered into a collaboration with The Linde Group to support its ongoing clinical research program to study a drug/device combination for treatment of patients with Post-Traumatic Stress Disorder (PTSD).

  4. MediciNova Announces Initiation Of Enrollment In A Clinical Trial Of MN-166 (ibudilast) In Glioblastoma
    1/8/2019

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first glioblastoma patient has enrolled in the clinical trial of MN-166 (ibudilast) in combination with temozolomide (TMZ, Temodar‑®) for the treatment of recurrent glioblastoma (GBM).

  5. Rafael Pharmaceuticals Announces Initiation Of Patient Enrollment For Phase II Clinical Trial Of CPI-613 For Patients With Relapsed Or Refractory Burkitt Lymphoma/Leukemia
    1/8/2019

    Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of patient enrollment for a phase II clinical trial of CPI-613 for patients with relapsed or refractory Burkitt Lymphoma/Leukemia.

  6. Lilly Announces Agreement To Acquire Loxo Oncology
    1/7/2019

    Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion.

  7. PAREXEL Introduces New Dedicated Division To Help Emerging Biotech Companies Reach Their Goals Quickly And Cost-Effectively
    1/6/2019

    PAREXEL International Corporation, a leading innovator of global biopharmaceutical services, recently introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.

  8. Sharp Investing $11m In Injectable And Cold Chain Capabilities
    1/4/2019

    Sharp – part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has announced an investment of $11 million to increase its global cold storage and syringe assembly capacity in response to market demand.

  9. ADC Therapeutics Doses First Patient In Phase Ib Clinical Trial Of ADCT-301 In Patients With Advanced Solid Tumors
    1/4/2019

    ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase Ib clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-301 (camidanlumab tesirine) in patients with selected solid tumors that are locally advanced or metastatic.

  10. Verrica Achieves Positive Topline Results From Two Pivotal Phase 3 Clinical Trials Of VP-102 In Patients With Molluscum Contagiosum
    1/4/2019

    Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced positive topline results from its Phase 3 CAMP-1 and CAMP-2 pivotal trials with VP-102 for the treatment of molluscum contagiosum (molluscum).